home / stock / achv / achv news


ACHV News and Press, Achieve Life Sciences Inc.

Stock Information

Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com

Menu

ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...

ACHV - Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch

2026-02-04 20:57:16 ET ... Read the full article on Seeking Alpha For further details see: Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch

ACHV - Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy

2026-02-04 02:43:16 ET Intro Achieve Life Sciences ( ACHV ) is a pre-commercial, late-stage pharmaceutical company that develops a smoking and vaping cessation therapy. It currently has no sales-generating business, as it is awaiting the FDA’s decision on whether its drug...

ACHV - Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers

2026-01-15 07:10:00 ET More on Disc Medicine, Sanofi, etc. Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Sanofi (SAN:CA)...

ACHV - Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation,...

ACHV - Achieve Life Sciences jumps on Hunterbrook Capital endorsement

2025-12-30 12:18:03 ET More on Achieve Life Sciences Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion Achieve Life Sciences outlines expedited FDA review for cytisi...

ACHV - Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that...

ACHV - Achieve Life Sciences outlines expedited FDA review for cytisinicline and targets Q3/Q4 2026 launch

2025-11-06 15:27:12 ET More on Achieve Life Sciences Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion Achieve Life Sciences: Promising Pipeline But High Risks Makes...

ACHV - Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

2025-11-06 15:26:10 ET Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

ACHV - Achieve Life Sciences GAAP EPS of -$0.28 misses by $0.02

2025-11-06 07:16:14 ET More on Achieve Life Sciences Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion Achieve Life Sciences: Promising Pipeline But High Risks Makes Me Hold For Now Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings...

ACHV - Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ac...

Next 10